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Far From Inert: The Consequences for Cell Biology of the Intrinsic Reactivity of 
Lipids in Membranes
John M Sanderson
Chemistry Department, Durham University, Durham, DH1 3LE, UK
Summary/Abstract
In this article it is hypothesised that a fundamental chemical reactivity exits between some 
non-lipid constituents of cellular membranes and ester-based lipids, the significance of 
which is not generally recognised. Many peptides and smaller organic molecules have now 
been shown to undergo lipidation reactions in model membranes in circumstances where 
direct reaction with the lipid is the only viable route for acyl transfer. Crucially, drugs like 
propranolol are lipidated in vivo with product profiles that are comparable to those 
produced in vitro. Some compounds have also been found to promote lipid hydrolysis. 
Drugs with high lytic activity in vivo tend to have higher toxicity in vitro. Deacylases and 
lipases are proposed as key enzymes that protect cells against the effects of intrinsic 
lipidation. The toxic effects of intrinsic lipidation are hypothesised to include a route by 
which nucleation can occur during the formation of amyloid fibrils.
1. Introduction
In their seminal paper on the Fluid Mosaic Model of the Structure of Cell Membranes, 
Singer and Nicolson stated that “…the phospholipids and proteins of membranes do not 
interact strongly; in fact, they appear to be largely independent”.[1] This statement is 
increasingly being challenged by the discovery of numerous processes that involve direct 
participation by membrane lipids. In addition to the non-covalent interactions that result, for 
example, in the formation of a boundary layer of lipids around a membrane protein[2] or 
changes to membrane curvature,[3] an accumulating body of evidence indicates that the 
chemical stability of the lipids that constitute the membrane can be significantly affected by 
the presence of non-lipid components in the membrane. Lipids that have ester-linked fatty 
acyl chains, such as diacylglycerophospholipids, have a surprisingly high intrinsic 
susceptibility towards lytic reactions involving nucleophilic attack at the carbonyl group. 
Both the catalysis of lipid hydrolysis by non-lipid components, leading to the formation of 
fatty acids and lysolipids (Figure 1),[4–6] and direct reactivity leading to fatty acyl group 
transfer from the lipid to the non-lipid component (i.e. a lipidation reaction), also with the 
concomitant formation of a lysolipid, [4,7–10] have been described. The term ‘intrinsic 
lipidation’ is used to describe this direct acyl transfer from a membrane lipid as the donor 
to a membrane-associated acceptor molecule.
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Figure 1. An overview of the reactions of ester-based lipids induced by non-lipidic 
components of the membrane. Acyl transfer from the lipid leads to intrinsic lipidation of the 
membrane-associated acyl acceptor in the leaflet to which the material is proximal, with 
the concomitant formation of one equivalent of lysolipid. Hydrolysis is catalytic, leading to 
the formation of multiple equivalents of fatty acid and lysolipid. Flip-flop of fatty acids 
between leaflets is usually much faster than that of lysolipids.[11] Adapted from 
https://commons.wikimedia.org/wiki/File:Cell_membrane_scheme.svg (CC-BY-SA-3.0-
migrated).
Salient hallmarks of intrinsic lipidation are: the presence of a broad spectrum of acyl 
modifications to the acceptor that reflect the fatty acid profile of the ester-based lipids in 
the membrane leaflet(s) in which the process occurs; and incomplete conversion, with 
residual unmodified acceptor remaining present. There is generally little selectivity for 
transfer from the sn-1 vs the sn-2 position of glycerol. The consequences of this 
generation of extrinsic lipidated material are difficult to predict and will depend to a large 
extent on specific molecular properties. In many cases, the addition of an acyl group is 
likely to endow the material with surfactant properties and increase the residency of the 
material in the membrane. Both lysolipids and fatty acids are known to have profoundly 
disruptive biological effects when generated in excess, including cytotoxicity and 
membrane permeability enhancement.[11] 
Lytic reactions of the kind outlined in Figure 1 potentially involve any molecule that is able 
to interact with a lipid membrane, regardless of size. The potential consequences of this 
reactivity therefore span a broad spectrum of biology, ranging from drug pharmacokinetics 
and mechanisms of toxicity for low molecular weight materials such as airborne pollutants, 
through disease mechanisms involving peptides, to post-translational changes to protein 
structure and function.
2. Lipidation Reactions Have Been Modelled In Vitro and Detected In Vivo
Lipidation reactions have been described in most detail for the peptide melittin using 
liposomes as a membrane model.[7,9,10] Other peptides are known to be reactive, including 
magainin II, penetratin and PGLa.[8] Typically, the sites to which acyl transfer occurs 
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include the N-terminal amino group, the ε-amino group of lysine, and the hydroxyl group of 
serine. Intrinsic lipidation exhibits selectivity not only in terms of the types of residue in the 
peptide structure that are modified, but also on their position within the structure. In the 
case of melittin for example (Figure 2), lipidation occurs predominantly at the N-terminus 
and the side chain of Lys23, although other sites are modified to a lesser extent, including 
Lys7, Lys21 and Ser18.[9] A common feature that links the predominant sites of 
modification is that they are predicted to reside at the interface between the hydrophilic 
and hydrophobic faces of the membrane-associated amphipathic helix.[8] 
1 11 21
a)
b) c)
hydrophobic face
hydrophilic face
K21
N-term
GIGAVLKVLT TGLPALISWI KRKRQQ-NH2
K23
K23
K21
S18
K7
G1 (N-term)
Figure 2. Melittin sequence and structure. a) Sequence. b) NMR structure (PDB entry: 
2MLT). Residues that are modified by intrinsic lipidation are shown as sticks. c) View down the 
helix axis with the C-terminus closest to the viewer. Lysine residues are shown in magenta, 
hydrophilic residues in blue and hydrophobic residues in grey.
The intrinsic lipidation behaviour of membrane-active peptides is highly sensitive to 
membrane composition. For example, following the addition of melittin to membranes 
composed of the neutral lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
approximately 20% of the molecules are lipidated after 24 h. The inclusion of negatively 
charged lipids, phosphatidylethanolamine (PE), or cholesterol significantly increases 
reactivity. When 20 mol% cholesterol is included in POPC membranes, more than 50% of 
the melittin sample is lipidated within 24 h, despite melittin having a lower binding affinity 
for these membranes. The presence of cholesterol also changes the relative selectivity of 
N-terminal vs Lys23 lipidation in comparison to the same system without cholesterol.[7]
To date, studies of peptide lipidation have been conducted in vitro using liposomes as 
model systems. Liposomes offer the advantage of enabling conditions to be precisely 
controlled and systematically varied, without the complications that arise from the 
presence of other potential acyl donors, such as acyl CoA derivatives. Limitations of this 
approach, when compared to the situation in vivo, are that: products in the model system 
are not turned over and consequently accumulate and potentially influence subsequent 
reactivity; experiments are often conducted at higher drug:lipid ratios than used in vitro; 
and due to the lack of other components of cell membranes such as proteins, and the 
absence of dynamic changes to membrane composition that can occur as a result of 
homeostasis, idealised conditions in vitro might not always accurately model the situation 
in vivo. However, all of these limitations are mitigated by recent data obtained from a study 
of drug reactivity in both model and cell membranes where, at physiologically relevant 
concentrations, similar product profiles were found in vitro and in cellulo in Hep G2 cells.[4] 
In this work it was found the drug propranolol undergoes lipidation predominantly on the 
central hydroxyl group in a process that is formally a transesterification reaction with the 
lipid (Figure 3). The predominant products detectable in Hep G2 cells after 24 h are 
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propranolol modified with the following acyl chains: C16:0 > C18:1 > C18:0 > C16:1 ~ 
C14:0, with C18:2, C20:1, C20:2, C20:3, C20:4 and C22:6 fatty acyl modifications also 
detectable as minor products. 
Figure 3. Lipidated propranolol species formed 24 h after administration of propranolol to 
Hep G2 cells. RC=O includes myristoyl, palmitoyl, palmitoleoyl, stearoyl and oleoyl, plus 
other minor products. 
Hydrolytic reactions are particularly prominent for cationic amphiphilic drugs, where the 
protonated form of the drug in the membrane interface is proposed to act as an acid 
catalyst for lipid hydrolysis.[5] Whilst detection of lipid hydrolysis is well established in 
liposome models,[6] there is currently no direct evidence for lysolipid formation in vivo. 
However, compounds that lead to significant lysis in liposome models also tend to have a 
lower EC50 for the lysosomal storage disorder phospholipidosis,[4] so there is some indirect 
evidence for a link between hydrolytic activity and biological activity. It will be of interest to 
probe whether other lysosomal storage diseases have a link to membrane chemical 
reactivity. 
3. Hypothesis: All Ester-based Lipids in Cellular Membranes Have a High 
Susceptibility to Lysis.
On consideration of the features of the intrinsic lipidation and hydrolysis reactions 
described above, the following hypothesis is proposed: all ester-based lipids in cellular 
membranes have a high susceptibility to lysis and this reactivity is enhanced by the 
presence of organic molecules with particular structural features. Lysis may be catalysed 
by the organic molecule, or be the result of direct chemical reaction between the organic 
molecule and the lipid.
On the basis of the data from the systems studied to date, some predictions may be made 
concerning the outcomes of this lytic reactivity should it occur in vivo:
1. The reactions will be very sensitive to changes in lipid and cholesterol composition 
and may therefore change significantly in situations where normal lipid homeostasis 
is disrupted.
2. Lipidation will produce products with both saturated and unsaturated fatty acyl 
groups due to a low sn-1/sn-2 selectivity.
3. For each lipidation site, a series of products should be present with a relative 
abundance that mirrors the fatty acid composition of the membrane leaflet in which 
the lipidated products form.
4. The lipidation process will be incomplete: unmodified material will be present.
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5. The presence of lysolipids formed by either hydrolysis or lipidation will perturb the 
lipid profile of the host cell.
If, as hypothesised, these lipid-lytic reactions are more prevalent than generally 
recognised, immediate questions arise concerning the reasons why their products are not 
more readily detectable and why they are not significantly deleterious to cell function. The 
answers to these questions may lie in the number of challenges to detecting these lytic 
processes in vivo:
1. Even when experiments are conducted in ideal conditions in vitro the amounts of 
lysolipid formed are often small relative to bulk lipid, particularly in typical scenarios 
where reactions do not go to completion, requiring the use of sensitive analytical 
methods. The detection of lysolipid products in vivo is likely to be even more 
challenging as a consequence of the likely perturbations to lipid homeostasis that 
follow from the formation of lysolipids. Chemical reactivity may actually appear as 
changes in the abundance of other lipid classes. For example, in the propranolol 
study there is some evidence that the relative abundance of plasmalogens was 
increased in Hep G2 cells after administration of propranolol.[4]
2. Detection of lipidated products is challenging due to the diversity of products 
formed, combined with the likelihood of an incomplete reaction. In many cases, 
lipidated products evade detection because they are insoluble or elute in the wash 
phase at the end of a proteomics run. For example, N-terminal lipidated fragments 
of aquaporin-0 were found in mobile phases with >95% acetonitrile during LC-MS 
analyses of tryptic digests of the protein.[12]
3. It is difficult to predict the likely sites of lipidation on any molecule because the 
reactivity is structure-based, depending to a significant degree on the relative 
positioning of the molecule with respect to the membrane. Currently, for peptides 
and proteins it is hugely problematic to use sequence-based methods to predict 
intrinsic lipidation sites as they do not correspond to enzyme consensus sequences.
4. Post-translational modifications by intrinsic lipidation will in some cases lead to 
other complications during protein digests. For example, internal lysine residues 
modified by acyl groups lead to missed cleavages in tryptic digests alongside mass 
increases (from the additional acyl groups) for the intact fragment.[9,12]
5. Lipidiation at other internal sites, such as the thiol group of cysteine, the hydroxyl 
group of serine and threonine, the imidazole of histidine and the guanidine of 
arginine will be difficult to detect due to the reasons presented above added to a 
higher tendency for these modifications to be hydrolysed during sample preparation 
and more facile in-source fragmentation during analysis by mass spectrometry.[9]
6. When considered in vivo, it may be difficult to rule out lipidation from other acyl 
donors, including acyl coenzyme A (CoA) derivatives. For both the propranolol and 
aquaporin work described above, it is difficult to eliminate completely the possibility 
that lipidation occurred from acyl CoA.[13–15]
Cells are likely to have evolved mechanisms to counter this reactivity. In the case of both 
hydrolysis and intrinsic lipidation, the lysolipid product will be subject to normal lipid 
homeostatic mechanisms,[16] as will the fatty acids formed by hydrolysis, being recycled for 
example into de novo synthesised lipids. Reversal of internal lipidation is discussed below.
4. Reversal of Acylation by Deacylases and Lipases.
Proteins modified at an internal lysine by intrinsic lipidation would require a deacylase 
activity to reverse the modification (Figure 1). Examples of both Class I and Class III 
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deacylases are known with the ability to catalyse the removal of long chain fatty acyl groups 
attached to lysine. Of the Class I enzymes, the histone deacetlyase HDAC8 was shown to remove 
fatty acyl modifications up to 14C in length (myristoyl) from an internal lysine of a model 
peptide.[17] In this case, the catalytic efficiency was greater for the removal of longer chain 
acyl groups than for acetyl. 
Of the Class III enzymes, several of the sirtuins are notable for possessing the ability to 
catalyse the removal of long acyl chains from internal lysine residues. Mammalian sirtuins 
are NAD+-dependent enzymes and are classified in 7 homologous groups (SIRT1–7) that 
differ in their substrate specificity and subcellular localisation.[18–21] Although their activity is 
often discussed in terms of deacetylation, most have the ability to catalyse the lysis of 
longer chain fatty acyl groups from the side chain of internal lysine residues,[22,23] with 
Sir2A (Plasmodium falciparum)[24], SIRT2 (cytoplasm)[25] and SIRT6 (nucleus)[20,23] shown 
to have particularly high selectivity for demyristoylation. SIRT2 has been linked with 
regulation of the activity of some Ras proteins via control of the deacylation of an internal 
lysine side chain.[26,27] It is notable that some sirtuins, such as SIRT6, are associated with 
disorders in lipid and fat metabolism such as steatosis.[28]
With the increasing availability of simultaneous inhibitors for multiple classes of sirtuin 
(pan-inhibitors),[18,29,30] it should be possible to probe the hypothesis that they are involved 
in reversing lysine modification by intrinsic lipidation by examining the downstream effects 
of sirtuin inhibition on the accumulation of proteins modified at internal lysines. This would 
complement experiments where reduced sirtuin activity has been shown to lead to 
hyperacetylation of histone proteins.[31]
Several good candidates for enzymes generally capable of reversing lipidation are found 
amongst the metabolic serine hydrolases[32] These include acylprotein thioesterases (also 
known as lysophospholipases), which are able to catalyse the hydrolysis of internally 
acylated serines and are also associated with the hydrolysis of a broad spectrum of 
lysolipids.[32] One of these, acylprotein thioesterase 1 (APT1) is present mostly in the 
cytosol, but has also been detected in many cellular membranes. Reversal of 
palmitoylation has been suggested to be a key function of this enzyme,[33] but deacylation 
of serine esters has also been reported.[34]
The hypothesis presented above predicts that the lysis products may not be evident under 
normal circumstances, either because they are only ever present at low levels or because 
they are relatively non-deleterious. It stands to reason then that if circumstances arise 
where either lytic products form that are highly toxic, or the balance between the 
generation and removal of lytic products is disrupted, then the products will become 
apparent. Potential scenarios for each of these cases will be presented below.
5. Membrane Protein Lipidation in the Absence of Deacylase Enzymes
Evidence of the potential effects of disrupting the balance between the generation and 
removal of lytic products can be found in scenarios where deacylase enzymes are not 
present. For example, lens fibre cells are post-mitotic, from which much of the normal 
cellular organelles and associated enzymes are removed during terminal differentiation.[35] 
Aquaporin-0 (AQP0) is a major component of the lens fibre membrane and is lipidated at 
two sites in the protein, the N-terminus and Lys238 (Figure S1), neither of which is 
predictable on the basis of known consensus sequences for lipidation enzymes. Both sites 
are modified with an unusual combination of acyl groups including C16:1, C18:0, C20:1, 
C20:3, and C20:2 for bovine AQP0 and C16:1, C18:0, C20:1 and C20:4 for human AQP0. 
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Neither site is completely lipidated. This combination of features bears all the hallmarks of 
an intrinsic lipidation process.[12]  
 
Another example may be found in pulmonary surfactant. This lipoprotein complex is rich in 
the lipid 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and surfactant proteins. One 
of these proteins, surfactant protein C, is palmitoylated at up to three internal sites, two of 
which are cysteine with the remaining one being a lysine (Lys11).[36–39] This lysine is 
predicted to reside in the vicinity of the membrane interface in the transmembrane 
protein.[40,41] Lipidation of the lysine is incomplete, as expected for a modification arising by 
intrinsic lipidation, giving rise to a series of products with differing numbers of additional 
palmitoyl groups.[36]
6. Peptide Conformational Changes Driven by Lipidation May Lead to Toxicity
 
It is well established that lipidation of membrane proteins can drive local conformational 
changes and influence both the membrane affinity of a protein and its lateral distribution 
within the membrane.[42–44] Lipidation can have even more pronounced effects on peptides 
that, when compared to proteins, are more likely to be unfolded when non-lipidated due to 
their smaller size and undergo a more pronounced overall change in hydrophobicity (or 
amphiphilicity) following the addition of a fatty acyl group. A number of peptides are known 
for which the lipidated form has both an increased tendency to self-aggregate and a higher 
affinity for lipid membranes, leading in both cases to the adoption of secondary structure at 
concentrations where the non-lipidat d form is a random coil. [45–52] Cases have also been 
documented where addition of an acyl group changes peptide aggregation behaviour and 
leads to the formation of fibrils rich in β-sheet. For example, short lysine-rich peptides 
derived from collagen adopt β-sheet conformations when palmitoylated and have a 
tendency to aggregate to form micelles or, in some cases, amyloid-like fibrils.[53,54] 
Amyloid-like fibril formation has also been reported for short lipidated peptides rich in β-
branched amino acids.[55]
Several peptides that are able to form insoluble amyloid fibrils have a significant affinity for 
lipid membranes and in many cases this binding is known to facilitate fibrillogenesis, 
through factors such as changes in secondary structure to favour β-sheet conformations or 
on-pathway helical intermediates and increased local concentrations on the membrane. 
[56–64] In the absence of membranes, numerous partially folded conformations (or 
microstates) exist in equilibrium with misfolded conformations. In appropriate 
circumstances, some of these misfolded conformations can nucleate to form oligomers 
(Figure 4a, path a). [58,59,65–69] Subsequent elongation of these oligomers leads to fibrils, 
with the overall kinetics controlled by the associated rate for nucleation and elongation. 
Nucleation is usually the rate determining step and is responsible for the observation of a 
lag phase during fibrillogenesis. In the prevailing view, peptide binding to membranes 
drives conformational change towards on-pathway fibril-forming aggregation intermediates 
and increases local concentrations of peptide (Figure 4a, path b), thereby increasing the 
rate of nucleation. An alternative view presented here, consistent with the intrinsic 
lipidation hypothesis, is that peptide lipidation is able to achieve similar outcomes of 
increasing local conformation and driving conformational change towards on-pathway 
intermediates (Figure 4a, path c) and occurs during the lag phase. There are several 
reasons why this hypothesis is appealing:
1. It can account for several observations that lipids are incorporated into fibrils. [59,70–
76] In cases where fluorescent lipids are used, the associated fluorescence of the 
fibrils could arise either from the formation mixed micelles of lipdated peptide and 
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lipid, or from direct transfer of a fluorescent acyl chain to the peptide during 
nucleation.
2. Nucleation by path c would be sensitive to a range of membrane-related factors that 
affect lipidation, such as surface potential, hydration (which is in turn affected by 
oxidation), and changes in lipidome as a result of ageing or disease,[77,78]. This 
sensitivity could account for numerous apparent contradictions or unexplained 
patterns of fibrillogenesis, such as the discrepancy between Aβ(1-40)[79] and Aβ(1-
42) [80] nucleation rates in neutral membranes, variations induced by the method of 
sample preparation,[73,81] and extracellular amyloid deposition remote from the site 
of peptide or protein formation.[65,82] 
3. The susceptibility to some amyloid diseases is inherited.[65,82] Intrinsic lipidation is 
sensitive to peptide interfacial orientation in the membrane. Changes in interfacial 
orientation or disposition might, for example, arise as a consequence of sequence 
changes that modify hydrophobicity or amphiphilicity. Lipidation is therefore able to 
provide a link between gene mutations and the susceptibility to amyloid formation.
4. The affinity of some amyloid-forming peptides for membranes with compositions 
representative of the plasma membrane is low.[80] Lipidation provides a mechanism 
to increase peptide affinity with these membranes.
5. Lipidated peptides associated with the membrane will be pre-oriented, have a high 
local concentration, and be able to diffuse freely in the plane of the membrane,[83] 
effectively transforming a 3D nucleation process into a 2D one with a much lower 
entropic energy barrier (Figure 4b).[84,85] 
b)a)
En
er
gy
Intramolecular Contacts Intermolecular Contacts
partially
folded
native
folding
intermediates oligomers
amorphous
aggregates
fibrils
unfolded
pa
th
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folded
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lipidated misfolded
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path a
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path c
lipidationdeacylaseor lipase
Figure 4. Protein folding pathways leading to the formation of fibrils. Path a is the 
nucleation pathway in the absence of membranes; path b is an alternative pathway in or 
on the membrane; path c involves facilitated nucleation by a low energy lipidated peptide 
formed by intrinsic lipidation. a) Schematic representation of key intermediates. Most 
aggregation intermediates comprise an ensemble of microstates. b) Energy level diagram. 
Some intermediates have been omitted for clarity. Adapted by permission from Springer 
Nature: Nature, Molecular chaperones in protein folding and proteostasis, Hartl et al., 
2011.[86]
Three cases where it may be hypothesised that lipidation plays are role are outlined 
below. One of these, amyloid Aβ, is described in more detail in Box 1; the other two, α-
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synuclein and Human Islet Amyloid Polypeptide, are discussed in more detail in the 
supporting information. 
The aggregation of the Aβ peptides such as Aβ(1-40) and Aβ(1-42) to form amyloid fibres 
is a key process during the progression of Alzheimer’s disease.[65,66,87] Aβ peptides are 
formed in neuronal cells by proteolytic processing of the amyloid precursor protein (APP) 
by γ-secretases (Figure 5).[84,88] APP has a single transmembrane helix and an 
extracellular hydrophilic domain. Many of the key sites cleaved by γ-secretases lie in the 
transmembrane region.[88,89] Recent work examining the conformation of Aβ(1-40) in lipid 
membranes has established that at low peptide to lipid ratios, Lys16, Ser26 and Lys28 
adopt dispositions close to the membrane interface in a partially helical structure, with 
subtle variations in peptide structure exhibited in neutral membranes according to the level 
of chain unsaturation.[90] 
The model shown in Figure 5a is proposed to account for a lipidation-based pathway for nucleation, 
whereby the cleavage of APP releases an Aβ peptide which retains some helical structure 
in solution[84,91–93] and undergoes reversible binding to the membrane that drives further 
structure formation towards an orientation that favours acyl transfer to the peptide at 
Lys16, Ser26 and Lys28. It is notable that Ser26 is in known to reside in the turn part of 
the β-structure[94] which would make this residue a good candidate for lipidation and 
presentation of the lipidated peptide in an orientation available to promote oligomerisation.  
Recent studies have also established that Ser26 and Lys23 are close to the membrane 
interface in the transmembrane topology of APP,[95] leading to an alternative pathway 
shown at the bottom of Figure 5a in which APP is lipidated before secretase cleavage. 
Appealing features of this shorter pathway are its brevity and the retention of the Aβ 
peptide in the membrane. The timescales for a lipidation-driven nucleation are reasonable, 
as even in systems with accelerated nucleation,[96] the nucleation half times are greater 
than one hour, putting them on the timescale that lipidation of melittin begins to be 
observable.[8,9]
Other cases where it may be hypothesised that intrinsic lipidation plays a role in nucleation 
include α-synuclein (α-syn) and Human Islet Amyloid Polypeptide (hIAPP). Deposition of 
α-syn in the central nervous system is associated with a number of disorders associated 
with ageing, including Parkinson’s disease.[97,98] The lysines of a KTKEGV repeat sequence of 
α-syn, which lie at the boundary between the hydrophilic and hydrophobic surfaces of a helix 
(Figure 6b), are potential lipidation sites. Good candidate residues include Lys43, Lys45, Lys58 and 
Lys60, in addition to one serine (Ser42). These residues lie close to the membrane interfacial 
region.[97] Additionally, on the basis of a high sensitivity of fibril formation to lipid composition, 
the presence of additional minor conformations when fibrils are formed in the presence of 
membranes, and additional α-syn mass accrued by post-translational modifications,[99] it is 
proposed that intrinsic lipidation (Figure 4, path c) is a valid nucleation pathway for this protein. 
Fibril formation by hIAPP in the pancreas is a feature of type 2 diabetes.[100] Lipid binding 
accelerates fibril formation and it has been established that hIAPP exhibits cooperative 
binding to membranes in a process that involves nucleation.[101] NMR relaxation 
experiments place two serine residues (Ser19 and Ser20) of hIAPP as potential lipidation 
sites in the membrane interface close to the boundary between the solvent exposed and 
fatty acyl chain exposed sections of the peptide (Figure 6c).[102]
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Figure 5. Proposed role of intrinsic lipidation in amyloid formation. a) Pathways for 
nucleation of Aβ peptides. Shown at the top, secretase cleavage of APP releases an Aβ 
peptide which undergoes reversible binding to the membrane in an orientation that favours 
acyl transfer to the peptide. An alternative route involving lipidation of APP before 
secretase cleavage is shown at the bottom. b) Residues 7 and 25 of the N-terminal section of 
α-syn (PDB entry 1XQ8 [103] viewed along the helix axis with residue 7 nearest the viewer. c) 
Residues 42–59 of hIAPP (PDB entry 2KB8), looking down the helix axis with residue 42 
closest to the viewer. In b) and c), amphiphilic sequences from amyloid forming peptides. 
Lysine and serine residues are shown in magenta, hydrophilic residues in blue and hydrophobic 
residues in grey.
The three cases outlined above are examples where intrinsic lipidation is hypothesised to 
operate as a nucleation pathway for fibril formation, in addition to the solution and 
membrane-associated pathways (Figure 4, paths a and b). The lipidation pathway is not 
limited to these three cases however, and may account for the features of a number of 
other protein misfolding diseases. In cases where regulatory agents such as chaperones 
prevent nucleation by paths a or b,[104] lipidation may provide the only route to nucleation. 
Proteins relevant for this lipidation hypothesis have the common feature, along with 
melittin, of existing as wholly or partially unstructured peptides in solution that adopt an 
amphipathic helical structure in the membrane that places reactive residues of lysine or 
serine close to reactive lipid carbonyl groups in the membrane interface. Lipidation may 
drive the peptides towards on-pathway intermediates and increase their membrane affinity, 
thereby promoting increased rates of nucleation. It should be recognised that proving this 
hypothesis is a very significant challenge, as it is implicit that intrinisic lipidation will affect 
only a very small proportion of peptides in the fibrillar structure that are buried at the sites 
of nucleation, and the nucleating centres themselves will have similar backbone 
conformations to the rest of the fibril around them. The modifications themselves, being 
esters in the case of serine and secondary amides in the case of lysine, are likely to be 
difficult to resolve spectroscopically from lipid esters and backbone amides respectively.
As a final point, it is worth considering whether the deamidases and lipases discussed 
above in section 4 can provide the same protection against nucleation via lipidation 
(Figure 4, path c) as chaperones can against protein misfolding in solution (Figure 4, path 
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a). Interestingly, many sirtuins have been reported to offer protection against Alzheimer’s 
disease and other neurodegenerative diseases that involve protein misfolding, such as 
Huntingdon’s disease and Parkinson’s disease.[105] Loss of SIRT6 activity is found in 
patients with Alzheimer’s disease,[106] whereas by contrast increasing SIRT6 activity is 
able to protect against Aβ42-induced DNA damage.[107] SIRT1 is downregulated in 
Parkinson’s disease, whereas SIRT1 over-expression reduces the formation of α-
synuclein aggregates in a neuroblastoma cell line in conditions of oxidative stress known 
to lead to the formation of protein aggregates.[108]
Box 1: The Role of Membranes in Aβ Fibrillogenesis
Binding of Aβ peptides to membranes leads to various effects, including detergent-like 
activity with the formation of micelle-like structures,[70] ion channel formation, and 
interfacial activities such as membrane fusion and disruption according to a carpet 
model.[109,110] At low coverage (i.e. a low peptide:lipid ratio) there is evidence for helical 
and partially folded conformations.[68,90] The composition of the membrane exerts a 
significant effect on the interactions of Aβ with membranes,[78,111] with even changes in the 
neutral lipid content affecting binding.[89] Binding affinity increases with an increase in 
negatively charged lipids and is affected by the presence of the ganglioside GM1.[110]
The inclusion of cholesterol in neutral and negatively charged membranes in vitro changes the 
binding characteristics of most Aβ peptides. For example, at 20 mol%, cholesterol hinders 
interaction of Aβ(25-35) with neutral membranes composed of unsaturated lipids.[112,113] By 
contrast, for membranes composed of saturated lipids, high cholesterol levels facilitate deeper 
penetration of Aβ(1-40),[114] and significantly increase nucleation rates of Aβ(1-42).[96] The 
behavior of Aβ peptides in vivo in the presence of cholesterol is complex to disentangle, not least 
because cholesterol levels change with cellula  location, age, disease, and under the influence of 
some medications.[115] Cholesterol levels also affect the activity of γ-secretases[87,116,117] and the 
distribution of APP.[118] In diseased brains, the cholesterol content of the temporal gyrus is 
significantly reduced when compared with non-diseased brains.[110]  This reduction will 
effect Aβ binding to the membrane, changing not only the strength of the interaction but 
also the penetration depth. Our work with melittin indicates that penetration depth is the 
more significant of the two factors in determining the rate at which lipidation occurs.[7] As a 
whole, these data indicate the there is a very real potential for small changes in cholesterol 
levels or lipid composition to place suitable Aβ residues in a position to undergo intrinsic 
lipidation. Consistent with this notion, NMR studies using 13C labelled amino acids incorporated 
into synthetic peptides suggest that Asp23 and Ser26 are close to lipid methylene groups.[73] The α-
C atoms of Gly25 and Val36 have also been demonstrated to have close contacts with 31P. [70]
There is some support for lipidated Aβ peptides being able to promote fibril formation. 
Short synthetically engineered fragments of amyloid Aβ palmitoylated on multiple lysine 
side chains adopt pathogenic fibrillar conformations in model membranes and are able to 
illicit an Aβ-specific immune response.[119,120] The β-sheet content of these peptides is 
influenced by the degree of lipidation, but in most cases they are able to assemble into 
fibrils in the absence of membranes.[121] Control peptides bearing acetyl groups in place of 
palmitoyl generally did not display this behaviour, remaining as random coil structures in 
solution. In some cases, the morphology of Aβ(1-40) fibrils formed in the presence of 
membranes has been found to differ from those formed in solution,[122] indicating that at 
least in some cases growing fibrils are able to access different intermediates in the 
fibrillation pathway.
7. Testing the Hypothesis
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The discussion above enables some predictions to be made that can be used to test the 
hypothesis that lipids are highly susceptible to lytic reactions.
Prediction 1: proteins are lipidated by chemical reactions with membrane lipids. The main 
obstacle to overcome in order to test this prediction is to demonstrate that fatty acyl 
modifications could not have occurred via the corresponding CoA derivatives. A tangible 
approach would be to supply a labelled fatty acid to an organism and ‘chase’ the label as it 
distributes through the lipids to the protein. The inclusion of CoA synthetase inhibitors at 
differing times and duration would enable the source of lipidation to be narrowed. 
 
Prediction 2: deacylases and lipases operate to correct proteins modified by intrinsic 
lipidation. As discussed above, proving this could be achieved, for example, by an 
observation of increased levels of lipidated proteins following the administration of pan-
inhibitors of sirtuins. 
Prediction 3: intrinsic lipidation plays a key role in some protein folding diseases. Direct 
proof of this involves identification of a small proportion of lipidated peptides within an 
insoluble fibre. There is a major obstacle in detecting minor modifications to an amino acid 
side chain that lie in the middle of an insoluble fibre. However, modern MS approaches 
such as ion mobility MS that offer improved methods for isolating minor species may offer 
an opportunity to detect these modifications.[123]
Prediction 4: lipid lysis generated by membrane-active agents is a factor in some 
lysosomal storage disorders. This prediction is challenging to demonstrate because the 
lysis of lipids generates lysolipids and fatty acids which, in vivo, will be redistributed by 
cellular homeostatic mechanisms and may or may not generate a subsequent adaptive 
response. One approach could be to probe lipid dynamics using pulse/chase experiments 
with a labelled lipid to prove that turnover increases in the presence of a lytic agent, 
combined with cell imaging to determine the temporo-spatial distribution of the pulse and 
identify its presence in structures such as lamellar bodies and lysosomes.
  
8. Conclusions
Intrinsic lipidation, involving direct acyl transfer from a lipid to an acceptor molecule, has 
been demonstrated in vitro in conditions where there are no possible competing processes 
that can involve enzymes or coenzyme A derivatives. It is therefore likely that conditions 
will exist under which this process will occur in vivo. The process should be particularly 
apparent where circumstances permit the accumulation of the intrinsically lipidated 
products, such as when protective measures to remove lipidated products are absent or 
the lipidated products themselves are toxic and/or insoluble. A significant conceptual 
challenge arises from the requirement to prove that acyl group modifications have arisen 
from the lipid rather than a coenzyme A derivative. It is nonetheless remarkable that 
molecules modified by multiple fatty acyl group modifications to a single site, ranging in 
size from whole proteins at one extreme to drug molecules at the other, have been 
isolated from biological samples. There are sufficient reasons to believe that both intrinsic 
lipidation and lipid hydrolysis catalysed by membrane-associated compounds could 
produce a number of detectable outcomes in cell biology. 
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An overview of the reactions of ester-based lipids induced by non-lipidic components of the membrane. Acyl 
transfer from the lipid leads to intrinsic lipidation of the membrane-associated acyl acceptor in the leaflet to 
which the material is proximal, with the concomitant formation of one equivalent of lysolipid. Hydrolysis is 
catalytic, leading to the formation of multiple equivalents of fatty acid and lysolipid. Flip-flop of fatty acids 
between leaflets is usually much faster than that of lysolipids.[11] Adapted from 
https://commons.wikimedia.org/wiki/File:Cell_membrane_scheme.svg (CC-BY-SA-3.0-migrated). 
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Melittin sequence and structure. a) Sequence. b) NMR structure (PDB entry: 2MLT). Residues that are 
modified by intrinsic lipidation are shown as sticks. c) View down the helix axis with the C-terminus closest 
to the viewer. Lysine residues are shown in magenta, hydrophilic residues in blue and hydrophobic residues 
in grey. 
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Lipidated propranolol species formed 24 h after administration of propranolol to Hep G2 cells. RC=O includes 
myristoyl, palmitoyl, palmitoleoyl, stearoyl and oleoyl, plus other minor products. 
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Protein folding pathways leading to the formation of fibrils. Path a is the nucleation pathway in the absence 
of membranes; path b is an alternative pathway in or on the membrane; path c involves facilitated 
nucleation by a low energy lipidated peptide formed by intrinsic lipidation. a) Schematic representation of 
key intermediates. Most aggregation intermediates comprise an ensemble of microstates. b) Energy level 
diagram. Some intermediates have been omitted for clarity. Adapted by permission from Springer Nature: 
Nature, Molecular chaperones in protein folding and proteostasis, Hartl et al., 2011.[86] 
170x78mm (300 x 300 DPI) 
Page 19 of 20
WILEY-VCH
BioEssays
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Proposed role of intrinsic lipidation in amyloid formation. a) Pathways for nucleation of Aβ peptides. Shown 
at the top, secretase cleavage of APP rel ases an Aβ peptide which undergoes reversible binding to the 
membrane in an orientation that favours acyl transfer to the peptide. An alternative route involving 
lipidation of APP before secretase cleavage is shown at the bottom. b) Residues 7 and 25 of the N-terminal 
section of α-syn (PDB entry 1XQ8 [103] viewed along the helix axis with residue 7 nearest the viewer. c) 
Residues 42–59 of hIAPP (PDB entry 2KB8), looking down the helix axis with residue 42 closest to the 
viewer. In b) and c), amphiphilic sequences from amyloid forming peptides. Lysine and serine residues are 
shown in magenta, hydrophilic residues in blue and hydrophobic residues in grey. 
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